SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

Jose Angel Garcia-Saenz; Isabel Blancas; Isabel Echavarria; Carmen Hinojo; Mireia Margeli; Fernando Moreno; Sonia Pernas; Teresa Ramon y Cajal; Nuria Ribelles; Meritxell Bellet

doi:10.1007/s12094-023-03203-8

SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

Jose Angel Garcia-Saenz^*, Isabel Blancas, Isabel Echavarria, Carmen Hinojo, Mireia Margeli, Fernando Moreno, Sonia Pernas, Teresa Ramon y Cajal, Nuria Ribelles, Meritxell Bellet

^*Autor corresponent d’aquest treball

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

16 Cites (Scopus)

Resum

Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.

Idioma original	Anglès
Pàgines (de-a)	2665-2678
Nombre de pàgines	14
Revista	Clinical and Translational Oncology
Volum	25
Número	9
DOIs	https://doi.org/10.1007/s12094-023-03203-8
Estat de la publicació	Publicada - de set. 2023

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1007/s12094-023-03203-8Llicència: Creative Commons Reconeixement

Altres arxius i enllaços

Enllaç a la publicació de Scopus

Com citar-ho

@article{9df75010d9b44a0c94e4d7ca455dafe9,

title = "SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)",

abstract = "Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.",

keywords = "ABC, ADC, Advanced breast cancer, Anti-HER2 therapy, Endocrine therapy, Guidelines, IOT",

author = "Garcia-Saenz, {Jose Angel} and Isabel Blancas and Isabel Echavarria and Carmen Hinojo and Mireia Margeli and Fernando Moreno and Sonia Pernas and {Ramon y Cajal}, Teresa and Nuria Ribelles and Meritxell Bellet",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = sep,

doi = "10.1007/s12094-023-03203-8",

language = "English",

volume = "25",

pages = "2665--2678",

number = "9",

}

TY - JOUR

T1 - SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

AU - Garcia-Saenz, Jose Angel

AU - Blancas, Isabel

AU - Echavarria, Isabel

AU - Hinojo, Carmen

AU - Margeli, Mireia

AU - Moreno, Fernando

AU - Pernas, Sonia

AU - Ramon y Cajal, Teresa

AU - Ribelles, Nuria

AU - Bellet, Meritxell

PY - 2023/9

Y1 - 2023/9

N2 - Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.

AB - Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.

KW - ABC

KW - ADC

KW - Advanced breast cancer

KW - Anti-HER2 therapy

KW - Endocrine therapy

KW - Guidelines

KW - IOT

UR - http://www.scopus.com/inward/record.url?scp=85158170365&partnerID=8YFLogxK

U2 - 10.1007/s12094-023-03203-8

DO - 10.1007/s12094-023-03203-8

M3 - Article

C2 - 37148499

AN - SCOPUS:85158170365

SN - 1699-048X

VL - 25

SP - 2665

EP - 2678

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

IS - 9

ER -

SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho